
Global Novel Oral AntiCoagulants (NOAC) Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Novel Oral AntiCoagulants (NOAC) market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Novel Oral AntiCoagulants (NOAC) include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Oral AntiCoagulants (NOAC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Oral AntiCoagulants (NOAC).
The Novel Oral AntiCoagulants (NOAC) market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Novel Oral AntiCoagulants (NOAC) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Novel Oral AntiCoagulants (NOAC) Segment by Company
Armatheon
Aspen
Boehringer Ingelheim
Bristol-Myers Squibb
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Daiichi Sankyo
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
AstraZeneca
Bayer
GSK
Johnson & Johnson
Sanofi
Eisai
Novel Oral AntiCoagulants (NOAC) Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Novel Oral AntiCoagulants (NOAC) Segment by Application
Hemodialysis
Deep Vein Thrombosis (DVT)
Acute Coronary Syndrome
Pulmonary Embolism
Others
Novel Oral AntiCoagulants (NOAC) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Novel Oral AntiCoagulants (NOAC) market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Novel Oral AntiCoagulants (NOAC) include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Oral AntiCoagulants (NOAC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Oral AntiCoagulants (NOAC).
The Novel Oral AntiCoagulants (NOAC) market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Novel Oral AntiCoagulants (NOAC) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Novel Oral AntiCoagulants (NOAC) Segment by Company
Armatheon
Aspen
Boehringer Ingelheim
Bristol-Myers Squibb
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Daiichi Sankyo
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
AstraZeneca
Bayer
GSK
Johnson & Johnson
Sanofi
Eisai
Novel Oral AntiCoagulants (NOAC) Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Novel Oral AntiCoagulants (NOAC) Segment by Application
Hemodialysis
Deep Vein Thrombosis (DVT)
Acute Coronary Syndrome
Pulmonary Embolism
Others
Novel Oral AntiCoagulants (NOAC) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
116 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Estimates and Forecasts (2020-2031)
- 1.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Estimates and Forecasts (2020-2031)
- 1.3 Novel Oral AntiCoagulants (NOAC) Market by Type
- 1.3.1 Direct Thrombin Inhibitors
- 1.3.2 Direct Factor Xa Inhibitors
- 1.4 Global Novel Oral AntiCoagulants (NOAC) Market Size by Type
- 1.4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Overview by Type (2020-2031)
- 1.4.2 Global Novel Oral AntiCoagulants (NOAC) Historic Market Size Review by Type (2020-2025)
- 1.4.3 Global Novel Oral AntiCoagulants (NOAC) Forecasted Market Size by Type (2026-2031)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2020-2025)
- 1.5.2 Europe Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2020-2025)
- 1.5.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2020-2025)
- 1.5.4 South America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2020-2025)
- 1.5.5 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2020-2025)
- 2 Global Market Dynamics
- 2.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
- 2.2 Novel Oral AntiCoagulants (NOAC) Industry Drivers
- 2.3 Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges
- 2.4 Novel Oral AntiCoagulants (NOAC) Industry Restraints
- 3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Novel Oral AntiCoagulants (NOAC) Revenue (2020-2025)
- 3.2 Global Top Players by Novel Oral AntiCoagulants (NOAC) Sales (2020-2025)
- 3.3 Global Top Players by Novel Oral AntiCoagulants (NOAC) Price (2020-2025)
- 3.4 Global Novel Oral AntiCoagulants (NOAC) Industry Company Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Novel Oral AntiCoagulants (NOAC) Major Company Production Sites & Headquarters
- 3.6 Global Novel Oral AntiCoagulants (NOAC) Company, Product Type & Application
- 3.7 Global Novel Oral AntiCoagulants (NOAC) Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Novel Oral AntiCoagulants (NOAC) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue in 2024
- 3.8.3 2023 Novel Oral AntiCoagulants (NOAC) Tier 1, Tier 2, and Tier 3
- 4 Novel Oral AntiCoagulants (NOAC) Regional Status and Outlook
- 4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size and CAGR by Region: 2020 VS 2024 VS 2031
- 4.2 Global Novel Oral AntiCoagulants (NOAC) Historic Market Size by Region
- 4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume by Region (2020-2025)
- 4.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Value by Region (2020-2025)
- 4.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales (Volume & Value), Price and Gross Margin (2020-2025)
- 4.3 Global Novel Oral AntiCoagulants (NOAC) Forecasted Market Size by Region
- 4.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume by Region (2026-2031)
- 4.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Value by Region (2026-2031)
- 4.3.3 Global Novel Oral AntiCoagulants (NOAC) Sales (Volume & Value), Price and Gross Margin (2026-2031)
- 5 Novel Oral AntiCoagulants (NOAC) by Application
- 5.1 Novel Oral AntiCoagulants (NOAC) Market by Application
- 5.1.1 Hemodialysis
- 5.1.2 Deep Vein Thrombosis (DVT)
- 5.1.3 Acute Coronary Syndrome
- 5.1.4 Pulmonary Embolism
- 5.1.5 Others
- 5.2 Global Novel Oral AntiCoagulants (NOAC) Market Size by Application
- 5.2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Overview by Application (2020-2031)
- 5.2.2 Global Novel Oral AntiCoagulants (NOAC) Historic Market Size Review by Application (2020-2025)
- 5.2.3 Global Novel Oral AntiCoagulants (NOAC) Forecasted Market Size by Application (2026-2031)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2020-2025)
- 5.3.2 Europe Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2020-2025)
- 5.3.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2020-2025)
- 5.3.4 South America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2020-2025)
- 5.3.5 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2020-2025)
- 6 Company Profiles
- 6.1 Armatheon
- 6.1.1 Armatheon Comapny Information
- 6.1.2 Armatheon Business Overview
- 6.1.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.1.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.1.5 Armatheon Recent Developments
- 6.2 Aspen
- 6.2.1 Aspen Comapny Information
- 6.2.2 Aspen Business Overview
- 6.2.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.2.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.2.5 Aspen Recent Developments
- 6.3 Boehringer Ingelheim
- 6.3.1 Boehringer Ingelheim Comapny Information
- 6.3.2 Boehringer Ingelheim Business Overview
- 6.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.3.5 Boehringer Ingelheim Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Comapny Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.4.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Cellceutix
- 6.5.1 Cellceutix Comapny Information
- 6.5.2 Cellceutix Business Overview
- 6.5.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.5.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.5.5 Cellceutix Recent Developments
- 6.6 Cosmo Pharmaceuticals
- 6.6.1 Cosmo Pharmaceuticals Comapny Information
- 6.6.2 Cosmo Pharmaceuticals Business Overview
- 6.6.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.6.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.6.5 Cosmo Pharmaceuticals Recent Developments
- 6.7 CSL Behring
- 6.7.1 CSL Behring Comapny Information
- 6.7.2 CSL Behring Business Overview
- 6.7.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.7.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.7.5 CSL Behring Recent Developments
- 6.8 Daiichi Sankyo
- 6.8.1 Daiichi Sankyo Comapny Information
- 6.8.2 Daiichi Sankyo Business Overview
- 6.8.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.8.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.8.5 Daiichi Sankyo Recent Developments
- 6.9 Marathon Pharmaceuticals
- 6.9.1 Marathon Pharmaceuticals Comapny Information
- 6.9.2 Marathon Pharmaceuticals Business Overview
- 6.9.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.9.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.9.5 Marathon Pharmaceuticals Recent Developments
- 6.10 Ockham Biotech
- 6.10.1 Ockham Biotech Comapny Information
- 6.10.2 Ockham Biotech Business Overview
- 6.10.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.10.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.10.5 Ockham Biotech Recent Developments
- 6.11 Perosphere
- 6.11.1 Perosphere Comapny Information
- 6.11.2 Perosphere Business Overview
- 6.11.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.11.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.11.5 Perosphere Recent Developments
- 6.12 AstraZeneca
- 6.12.1 AstraZeneca Comapny Information
- 6.12.2 AstraZeneca Business Overview
- 6.12.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.12.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.12.5 AstraZeneca Recent Developments
- 6.13 Bayer
- 6.13.1 Bayer Comapny Information
- 6.13.2 Bayer Business Overview
- 6.13.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.13.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.13.5 Bayer Recent Developments
- 6.14 GSK
- 6.14.1 GSK Comapny Information
- 6.14.2 GSK Business Overview
- 6.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.14.5 GSK Recent Developments
- 6.15 Johnson & Johnson
- 6.15.1 Johnson & Johnson Comapny Information
- 6.15.2 Johnson & Johnson Business Overview
- 6.15.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.15.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.15.5 Johnson & Johnson Recent Developments
- 6.16 Sanofi
- 6.16.1 Sanofi Comapny Information
- 6.16.2 Sanofi Business Overview
- 6.16.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.16.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.16.5 Sanofi Recent Developments
- 6.17 Eisai
- 6.17.1 Eisai Comapny Information
- 6.17.2 Eisai Business Overview
- 6.17.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2020-2025)
- 6.17.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
- 6.17.5 Eisai Recent Developments
- 7 North America by Country
- 7.1 North America Novel Oral AntiCoagulants (NOAC) Sales by Country
- 7.1.1 North America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.1.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2025)
- 7.1.3 North America Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2026-2031)
- 7.2 North America Novel Oral AntiCoagulants (NOAC) Market Size by Country
- 7.2.1 North America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2.2 North America Novel Oral AntiCoagulants (NOAC) Market Size by Country (2020-2025)
- 7.2.3 North America Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2026-2031)
- 8 Europe by Country
- 8.1 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country
- 8.1.1 Europe Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.1.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2025)
- 8.1.3 Europe Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2026-2031)
- 8.2 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country
- 8.2.1 Europe Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2.2 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country (2020-2025)
- 8.2.3 Europe Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific by Country
- 9.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country
- 9.1.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.1.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2025)
- 9.1.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2026-2031)
- 9.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country
- 9.2.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country (2020-2025)
- 9.2.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2026-2031)
- 10 South America by Country
- 10.1 South America Novel Oral AntiCoagulants (NOAC) Sales by Country
- 10.1.1 South America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.1.2 South America Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2025)
- 10.1.3 South America Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2026-2031)
- 10.2 South America Novel Oral AntiCoagulants (NOAC) Market Size by Country
- 10.2.1 South America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2.2 South America Novel Oral AntiCoagulants (NOAC) Market Size by Country (2020-2025)
- 10.2.3 South America Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2026-2031)
- 11 Middle East and Africa by Country
- 11.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country
- 11.1.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.1.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2025)
- 11.1.3 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2026-2031)
- 11.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country
- 11.2.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country (2020-2025)
- 11.2.3 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2026-2031)
- 12 Value Chain and Sales Channels Analysis
- 12.1 Novel Oral AntiCoagulants (NOAC) Value Chain Analysis
- 12.1.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Novel Oral AntiCoagulants (NOAC) Production Mode & Process
- 12.2 Novel Oral AntiCoagulants (NOAC) Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
- 12.2.3 Novel Oral AntiCoagulants (NOAC) Customers
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.